Vibeke Strand

Vibeke Strand

Auto-generated profile, based on publicly available information

Vibeke Strand

Biopharmaceutical Consultant, Portola Valley, CA, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 1999 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
VSVibeke Strand
Vibeke Strand
SCStanley Cohen
Stanley Cohen
MSMichael Schiff
Michael Schiff
AWArthur Weaver
Arthur Weaver
RFRoy Fleischmann
Roy Fleischmann
ILIris Loew-Friedrich
Iris Loew-Friedrich
CURRENT treatments for rheumatoid arthritis (RA) include nonsteroidal anti-inflammatory drugs (NSAIDs), low-dose steroids, and disease-modifying antirheumatic drugs (DMARDs). The active control drug for this study, methotrexate, is considered to be the "gold standard" DMARD for the treatment of RA.1-4 No currently available medication is uniformly effective, however, and all may cause significant adverse effects.5

26 November 2007 in Trials
Verified
Journal Article
Open access
PDF file
PTPeter Tugwell
Peter Tugwell
MBMaarten Boers
Maarten Boers
PBPeter Brooks
Peter Brooks
LSLee Simon
Lee Simon
VSVibeke Strand
Vibeke Strand
LILeanne Idzerda
Leanne Idzerda
OMERACT is the acronym for an international, informally organized network initiated in 1992 aimed at improving outcome measurement in rheumatology. Chaired by an executive committee, it organizes consensus conferences in a 2-yearly cycle that circles the globe. Data driven recommendations are prepared and updated by expert working groups. Recommendations include core sets of measures for most of the major rheumatologic conditions. Since 2002 patients have been actively engaged in the process.

8 October 2009 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
PMPhilip Mease
Philip Mease
LALesley M. Arnold
Lesley M. Arnold
ECErnest H. Choy
Ernest H. Choy
DCDaniel Clauw
Daniel Clauw
LCLeslie J. Crofford
Leslie J. Crofford
DWDavid A. Williams
David A. Williams
The objective of the module was to (1) establish a core domain set for fibromyalgia (FM) assessment in clinical trials and practice, (2) review outcome measure performance characteristics, (3) discuss development of a responder index for assessment of FM in clinical trials, (4) review objective markers, (5) review the domain of cognitive dysfunction, and (6) establish a research agenda for outcomes research. Presentations at the module included: (1) Results of univariate and multivariate analysis of 10 FM clinical trials of 4 drugs, mapping key domains identified in previous patient focus group: Delphi exercises and a clinician/researcher Delphi exercise, and breakout discussions to vote on possible essential domains and reliable measures; (2) Updates regarding outcome measure status; (3) Update on objective markers to measure FM disease state; and (4) Review of the issue of cognitive dysfunction (dyscognition) in FM. Consensus was reached as follows: (1) Greater than 70% of OMERACT participants agreed that pain, tenderness, fatigue, patient global, multidimensional function and sleep disturbance domains should be measured in all FM clinical trials; dyscognition and depression should be measured in some trials; and stiffness, anxiety, functional imaging, and cerebrospinal fluid biomarkers were identified as domains of research interest. (2) FM domain outcome measures have generally proven to be reliable, discriminative, and feasible. More sophisticated and comprehensive measures are in development, as is a responder index for FM. (3) Increasing numbers of objective markers are being developed for FM assessment. (4) Cognitive dysfunction assessment by self-assessed and applied outcome measures is being developed. In conclusion, a multidimensional symptom core set is proposed for evaluation of FM in clinical trials. Research on improved measures of single domains and composite measures is ongoing.

23 March 2004 in Rheumatology
Verified
Journal Article
Open access
PDF file
VSV. Strand
V. Strand
FGfor the Leflunomide Investigators Groups
for the Leflunomide Investigators Groups
SCS. Cohen
S. Cohen
BCB. Crawford
B. Crawford
JSJ. S. Smolen
J. S. Smolen
DSD. L. Scott
D. L. Scott
Background. Recent randomized controlled trials (RCTs) in rheumatoid arthritis (RA) have used patient- and physician-reported outcomes, ESR and/or CRP as components of ACR response criteria to assess efficacy. Objectives. Mean changes from baseline in patient- and physician-reported outcome measures, ESR and CRP were compared in two RCTs in patients with active RA. Comparisons between active and placebo treatment used mean percentage improvements and standard effect sizes (SESs). Results. In both protocols, patient-reported assessments of disease activity, pain and physical function reflected little or no improvement with placebo, best discriminating between active and placebo therapy, as did ESR and CRP. Conclusion. Improvements in signs and symptoms of active RA in placebo RCTs appear to be best reflected by patient-reported measures of physical function, as long as reported changes in global assessments of disease activity and/or pain reflect similar benefit. Patient-reported outcome measures should be considered objective; treatment-associated changes are congruent with measures of inflammation, and appear less susceptible to the placebo response.

1 September 2003 in Lupus
Verified
Journal Article
Closed access
VSV Strand
V Strand
CAC Aranow
C Aranow
MCM H Cardiel
M H Cardiel
DAD Alarcón-Segovia
D Alarcón-Segovia
RFR Furie
R Furie
BCB Crawford
B Crawford
In a 76-week, randomized controlled trial, patients received 100mg LJP 394 or placebo weekly for 16 weeks followed by three 12-week treatment cycles of 50mg LJP 394 or placeboweekly each separated ...

1 June 2005 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Closed access
VSVibeke Strand
Vibeke Strand
BCBruce Crawford
Bruce Crawford
Patients with systemic lupus erythematosus experience a decreased health-related quality of life due to disease activity, multisystem organ involvement and frequent hospitalization. High levels of anti-double-stranded DNA antibodies are associated with renal disease, a primary cause of morbidity and mortality in systemic lupus erythematosus, and progressive cognitive dysfunction. Post hoc analyses of two clinical trials of abetimus sodium identified responders with sustained reductions in anti-double-stranded DNA antibodies. At 6 and 12 months, responders reported improvement in health-related quality of life, as measured by the Medical Outcomes Survey Short Form 36, compared with no change or deterioration in nonresponders. Sustained reductions in anti-double-stranded DNA antibodies, regardless of treatment group, led to clinically meaningful improvements in patient-reported health-related quality of life.